TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/5/21 20:58 | 12/31/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schiermeier Andrew | MA | O | EVP,COO | M.d | 0 | 0.00 | 0 | 5 | 40 | 17 | D | ||||||||||||||
1/5/21 20:58 | 1/5/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schiermeier Andrew | MA | O | EVP,COO | S.d | -77 | 55.86 | 0 | -1 | -8 | 17 | D | ||||||||||||||
1/4/21 21:03 | 12/30/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schiermeier Andrew | MA | O | EVP,COO | M.d | 20 | 13.48 | 0 | 2 | 13 | 13 | D | ||||||||||||||
3/12/19 16:38 | 3/6/19 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schiermeier Andrew | MA | O | EVP,Dev, | P | 118 | 15.72 | 0 | 8 | 87 | 16 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |